Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, January 2016



Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. Tseng YC1, Kulp SK1, Lai IL1, et al. J Natl Cancer Inst. 2015 Oct 12;107(12):djv274. doi: 10.1093/jnci/djv274. Print 2015 Dec.

Naringenin ameliorates inflammation and cell proliferation in benzo(a)pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFκB and PCNA expression. Bodduluru LN1, Kasala ER2, Madhana RM2, et al. Int Immunopharmacol. 2016 Jan;30:102-10. doi: 10.1016/j.intimp.2015.11.036. Epub 2015 Dec 4.

Whole exome sequencing reveals genetic variability among lung cancer cases sub-phenotyped for emphysema. Lusk CM1, Wenzlaff AS1, Dyson G1, et al. Carcinogenesis. 2015 Dec 30. pii: bgv248. [Epub ahead of print]

Single-cell detection of EGFR gene mutation in circulating tumor cells in lung cancer. Shuai S1, Yuliang D1. Yi Chuan. 2015 Dc;37(12):1251-7. doi: 10.16288/j.yczz.15-130.

Differential Serum Cytokine Levels and Risk of Lung Cancer between African and European Americans. Pine SR1, Mechanic LE2, Enewold L3, et al. Cancer Epidemiol Biomarkers Prev. 2015 Dec 28. pii: cebp.0378.2015. [Epub ahead of print]

Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. Mizuno K1, Seki N2, Mataki H1, et al. Int J Oncol. 2016 Feb;48(2):450-60. doi: 10.3892/ijo.2015.3289. Epub 2015 Dec 14.


Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study. Tanner NT, Aggarwal J, Gould MK, Kearney P, Diette G, Vachani A, Fang KC, Silvestri GA. Chest. 2015 Dec 1;148(6):1405-14. doi: 10.1378/chest.15-0630.

Improved Lung Cancer Detection in Cardiovascular Outpatients by the Pulmonologist-based Interpretation of Chest Radiographs. Sakai M1, Kato A, Kobayashi N, Nakamura R, Okawa S, Sato Y. Intern Med. 2015;54(23):2991-7. doi: 10.2169/internalmedicine.54.4171. Epub 2015 Dec 1.

Using “residual” FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience. Wei S1, Lieberman D1, Morrissette JJ1, Baloch ZW1, Roth DB1, McGrath C1. Cancer Cytopathol. 2015 Dec 18. doi: 10.1002/cncy.21666. [Epub ahead of print]

Clinical implications of positive margins following non-small cell lung cancer surgery. Predina JD1, Keating J1, Patel N1, Nims S1, Singhal S1. J Surg Oncol. 2015 Dec 30. doi: 10.1002/jso.24130. [Epub ahead of print]

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Steuer CE1, Behera M1, Berry L2, et al. Cancer. 2015 Dec 22. doi: 10.1002/cncr.29812. [Epub ahead of print]

Lung cancer screening: what do long-term smokers know and believe? Carter-Harris L1, Ceppa DP2, Hanna N2,3, Rawl SM1. Health Expect. 2015 Dec 23. doi: 10.1111/hex.12433. [Epub ahead of print]

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

Ulivi P1, Chiadini E2, Dazzi C2, et al. Clin Lung Cancer. 2015 Dec 1. pii: S1525-7304(15)00268-5. doi: 10.1016/j.cllc.2015.11.004. [Epub ahead of print]

Lung Cancer Screening With Low-Dose CT in the United States. Eberth JM1. J Am Coll Radiol. 2015 Dec;12(12 Pt B):1395-402. doi: 10.1016/j.jacr.2015.09.016.

Primary Care Providers and a System Problem: A Qualitative Study of Clinicians Caring for Patients With Incidental Pulmonary Nodules. Golden SE, Wiener RS, Sullivan D, Ganzini L, Slatore CG. Chest. 2015 Dec 1;148(6):1422-9. doi: 10.1378/chest.14-2938.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. Asamura H1, Chansky K, Crowley J, et al. J Thorac Oncol. 2015 Dec;10(12):1675-84. doi: 10.1097/JTO.0000000000000678.

Early Results From the Implementation of a Lung Cancer Screening Program: The Beaumont Health System Experience. Lanni TB Jr1, Stevens C, Farah M, Boyer A, Davis J, Welsh R, Keena D, Akhtar A, Mezwa D. Am J Clin Oncol. 2015 Dec 8. [Epub ahead of print]


Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy. Puri V1, Crabtree TD, Bell JM, et al. J Thorac Oncol. 2015 Dec;10(12):1776-84. doi: 10.1097/JTO.0000000000000680.

Long-term survival following open versus thoracoscopic lobectomy after preoperative chemo-therapy for non-small cell lung cancer†. Yang CJ1, Meyerhoff RR1, Mayne NR1, et al. Eur J Cardiothorac Surg. 2015 Dec 30. pii: ezv428. [Epub ahead of print]

Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: A prospective randomised double-blinded trial. Lee SH1, Kim N, Lee CY, Ban MG, Oh YJ. Eur J Anaesthesiol. 2015 Dec 24. [Epub ahead of print]

Lobectomy for Non-Small Cell Lung Cancer by Video-Assisted Thoracic Surgery: Effects of Cumulative Institutional Experience on Adequacy of Lymphadenectomy. Lee PC1, Kamel M2, Nasar A2, et al. Ann Thorac Surg. 2015 Dec 1. pii: S0003-4975(15)01581-7. doi: 10.1016/j.athoracsur.2015.09.073. [Epub ahead of print]

Surgical Outcomes after Pulmonary Resection for Non-Small Cell Lung Cancer with Localized Pleural Seeding First Detected during Surgery. Yun JK1, Kim MA2, Choi CM2, et al. Thorac Cardiovasc Surg. 2015 Dec 15. [Epub ahead of print]

Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer†. Yang CJ1, Adil SM1, Anderson KL1, et al. Eur J Cardiothorac Surg. 2015 Dec 30. pii: ezv431. [Epub ahead of print]


Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01. Fournel P1, Vergnenégre A2, Robinet G3, et al. Eur J Cancer. 2016 Jan;52:181-7. doi: 10.1016/j.ejca.2015.10.072. Epub 2015 Dec 12.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Herbst RS1, Baas P2, Kim DW3, et al. Lancet. 2015 Dec 18. pii: S0140-6736(15)01281-7. doi: 10.1016/S0140-6736(15)01281-7. [Epub ahead of print]

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Shaw AT1, Gandhi L2, Gadgeel S3, et al. Lancet Oncol. 2015 Dec 18. pii: S1470-2045(15)00488-X. doi: 10.1016/S1470-2045(15)00488-X. [Epub ahead of print]

Adaptive neoadjuvant chemotherapy guided by 18F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial. Chaft JE1, Dunphy M2, Naidoo J3, et al. J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00266-X. doi: 10.1016/j.jtho.2015.12.104. [Epub ahead of print]

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Schuler M, Yang JC, Park K, et al. Ann Oncol. 2015 Dec 8. pii: mdv597. [Epub ahead of print]

Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Park HS1, Lim SM, Cho A, Shin JG, Lee MG, Kim HR, Kim JH, Shin HJ, Cho BC. Pharmacogenet Genomics. 2015 Dec 4. [Epub ahead of print]

Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Isozaki H1, Ichihara E2, Takigawa N3, et al. Cancer Res. 2015 Dec 30. pii: canres.1010.2015. [Epub ahead of print]


Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. Daly ME1, Monjazeb AM, Kelly K. J Thorac Oncol. 2015 Dec;10(12):1685-93. doi: 10.1097/JTO.0000000000000686.

Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Zhuang H1, Zheng Y2, Wang J3, Chang JY4, Wang X1, Yuan Z1, Wang P1. Oncotarget. 2015 Dec 10. doi: 10.18632/oncotarget.6532. [Epub ahead of print]




The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Xiao XG1, Xia S1, Zou M1, Mei Q1, Zhou L1, Wang SJ1, Chen Y1. Onco Targets Ther. 2015 Dec 3;8:3575-83. doi: 10.2147/OTT.S95149. eCollection 2015.

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263. Greenberg EF1,2,3, McColl KS1,3, Zhong F1,3, Wildey G1,3, Dowlati A1,3, Distelhorst CW1,3. Cell Death Dis. 2015 Dec 31;6:e2034. doi: 10.1038/cddis.2015.355.

Pleural Small Cell Lung Carcinoma: An Unusual Culprit in Pleural Effusion. Adejorin OD1, Sodhi A1, Hare FA1, Headley AS1, Murillo LC1, Kadaria D1. Am J Case Rep. 2015 Dec 30;16:912-5.

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer. Nosaki K1, Seto T2. Curr Treat Options Oncol. 2015 Dec;16(12):56. doi: 10.1007/s11864-015-0372-2.

Positive Interaction Between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). Salama JK1, Gu L2, Wang X2, et al. J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00049-0. doi: 10.1016/j.jtho.2015.11.001. [Epub ahead of print]

Utilization of Hyperfractionated Radiation in Small-Cell Lung Cancer and Its Impact on Survival. Schreiber D1, Wong AT, Schwartz D, Rineer J. J Thorac Oncol. 2015 Dec;10(12):1770-5. doi: 10.1097/JTO.0000000000000672.

Bromodomain and hedgehog pathway targets in small cell lung cancer. Kaur G1, Reinhart RA2, Monks A2, Evans D2, Morris J3, Polley E4, Teicher BA5. Cancer Lett. 2015 Dec 10. pii: S0304-3835(15)00737-5. doi: 10.1016/j.canlet.2015.12.001. [Epub ahead of print]


Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. Tseng YC1, Kulp SK1, Lai IL1, et al. J Natl Cancer Inst. 2015 Oct 12;107(12):djv274. doi: 10.1093/jnci/djv274. Print 2015 Dec.

Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. Koshy M1, Malik R2, Mahmood U2, Husain Z2, Weichselbaum RR2, Sher DJ2. J Natl Cancer Inst. 2015 Sep 30;107(12):djv278. doi: 10.1093/jnci/djv278. Print 2015 Dec.

Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain. Fallon M1, Hoskin PJ2, Colvin LA2, et al. J Clin Oncol. 2015 Dec 7. pii: JCO.2015.63.8221. [Epub ahead of print]

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. Fiteni F1, Vernerey D2, Bonnetain F3, et al. Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10.

Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status? Robinson AG1, Young K2, Balchin K3, Owen T1, Ashworth A1. Curr Oncol. 2015 Dec;22(6):399-404. doi: 10.3747/co.22.2689.

Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1. Miyauchi E1, Motoi N, Ono H, Ninomiya H, Ohyanagi F, Nishio M, Okumura S, Ichinose M, Ishikawa Y. Medicine (Baltimore). 2015 Dec;94(51):e2324. doi: 10.1097/MD.0000000000002324.

Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents. Castellanos EH1, Chen SC1, Drexler H1, Horn L1. J Natl Compr Canc Netw. 2015 Dec;13(12):1490-5.

Prognosis, Treatment Benefit and Goals of Care: What do Oncologists Discuss with Patients who have Incurable Cancer? Raskin W1, Harle I2, Hopman WM3, Booth CM4. Clin Oncol (R Coll Radiol). 2015 Dec 14. pii: S0936-6555(15)00446-X. doi: 10.1016/j.clon.2015.11.011. [Epub ahead of print]


Tai Chi Exercise for Cancer-Related Fatigue in Patients with Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial. Zhang LL1, Wang SZ2, Chen HL3, Yuan AZ4. J Pain Symptom Manage. 2015 Dec 22. pii: S0885-3924(15)00989-6. doi: 10.1016/j.jpainsymman.2015.11.020. [Epub ahead of print]

Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. Chung VCh1,2, Wu X1,2, Hui EP1,3, et al. Sci Rep. 2015 Dec 16;5:18111. doi: 10.1038/srep18111.

Wenxia Changfu Formula () induces apoptosis of lung adenocarcinoma in a transplanted tumor model of drug-resistance nude mice. Ji XM1, Wu ZC2, Liu GW1, Yu HY1, Liu H3, Wang ZT4, Wei XH4, Ouyang B1. Chin J Integr Med. 2015 Dec 14. [Epub ahead of print]

Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases. Ma L1, Wang R1, Nan Y1, Li W1, Wang Q2, Jin F1. Int J Oncol. 2016 Feb;48(2):843-53. doi: 10.3892/ijo.2015.3304. Epub 2015 Dec 21.


Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. Kreamer K1, Riordan D1. Clin J Oncol Nurs. 2015 Dec 1;19(6):734-42. doi: 10.1188/15.CJON.734-742.

A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System. Lin J1, Carter CA, McGlynn KA, Zahm SH, Nations JA, Anderson WF, Shriver CD, Zhu K. J Thorac Oncol. 2015 Dec;10(12):1694-702. doi: 10.1097/JTO.0000000000000691.

Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. Pfister DG1, Rubin DM1, Elkin EB1, Neill US1, Duck E1, Radzyner M1, Bach PB1. JAMA Oncol. 2015 Dec 1;1(9):1303-10. doi: 10.1001/jamaoncol.2015.3151.

Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. Goldstein DA1, Chen Q2, Ayer T2, et al. JAMA Oncol. 2015 Dec 1;1(9):1293-300. doi: 10.1001/jamaoncol.2015.3316.

Racial Differences in Tobacco Cessation and Treatment Usage After Lung Screening: An Examination of the National Lung Screening Trial. Kumar P1, Gareen IF2, Lathan C3, Sicks JD4, Perez GK5, Hyland KA6, Park ER5. Oncologist. 2015 Dec 28. pii: theoncologist.2015-0325. [Epub ahead of print]

Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. Lin JJ1, Cardarella S2, Lydon CA2, Dahlberg SE3, Jackman DM4, Jänne PA4, Johnson BE5. J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00265-8. doi: 10.1016/j.jtho.2015.12.103. [Epub ahead of print]

Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women’s Health Initiative. Patel MI1, Wang A2, Kapphahn K2, et al. J Clin Oncol. 2015 Dec 23. pii: JCO635789. [Epub ahead of print]

Chronic Disease Diagnosis as a Teachable Moment for Health Behavior Changes Among Middle-Aged and Older Adults. Xiang X1. J Aging Health. 2015 Dec 2. pii: 0898264315614573. [Epub ahead of print]

Cancer incidence among Asian American populations in the United States, 2009-2011. Jin H1, Pinheiro PS1, Xu J2, Amei A2. Int J Cancer. 2015 Dec 13. doi: 10.1002/ijc.29958. [Epub ahead of print]

Hospice Use, Hospitalization, and Medicare Spending at the End of Life. Zuckerman RB1, Stearns SC2, Sheingold SH3. J Gerontol B Psychol Sci Soc Sci. 2015 Dec 11. pii: gbv109. [Epub ahead of print]

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Govindan R1, Mandrekar SJ2, Gerber DE3, et al. Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354.


Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)